<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02160743</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_ATM_104</org_study_id>
    <nct_id>NCT02160743</nct_id>
  </id_info>
  <brief_title>The Food Effect on Pharmacokinetics and Safety of Fixed-dose Combination of CJ-30056 in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the food effect on pharmacokinetics and safety of fixed-dose combination
      of &quot;CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)&quot; in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of atorvastatin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of metformin</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration versus time curve (AUC0-t) of atorvastatin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration versus time curve (AUC0-t) of metformin</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of 2-OH-atorvastatin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of atorvastatin and metformin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24, 36 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma concentration versus time curve (AUC0-t) of 2-OH-atorvastatin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Atorvastatin, 2-OH-atorvastatin and metformin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24, 36 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Atorvastatin, 2-OH-atorvastatin and metformin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24, 36 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β of Atorvastatin, 2-OH-atorvastatin and metformin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24, 36 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of atorvastatin and metformin</measure>
    <time_frame>0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24, 36 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Food Effect Study of CJ-30056 20mg/500mg</condition>
  <arm_group>
    <arm_group_label>CJ-30056 20mg/500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fasting, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fed, fasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)</intervention_name>
    <arm_group_label>CJ-30056 20mg/500mg</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to adhere to protocol requirements and sign a informed consent form

          2. Male volunteers in the age between 20 and 45 years old and have the weight range is
             not exceed ±20% of ideal weight

          3. Subjects with no history of any significant chronic disease

          4. Judged to be in good health on the basis of their vital sign, ECG, physical exam and
             routine laboratory data

        Exclusion Criteria:

          1. Use of barbital inducer or inhibitor medication within the 4 weeks before dosing

          2. Symptom of an acute illness within 4 weeks prior to drug administration

          3. History of clinically significant hepatic, renal, gastrointestinal diseases which
             might significantly interfere with ADME

          4. History of surgery except or gastrointestinal diseases which might significantly
             change absorption of medicines

          5. History of clinically significant allergies including drug allergies

          6. History of clinically significant allergies about atorvastatin or metformin

          7. Subjects who have ever or have plan to do intravenous injection of contrast medium
             (intravenous urography, intravenous cholangiography, computed tomography using
             contrast medium) within 28 days prior to drug administration

          8. History of myopathy

          9. Clinical laboratory test values are outside the accepted normal range

               -  AST or ALT &gt;1.25 times to normal range

               -  Total bilirubin &gt;1.5 times to normal range

               -  e-GFR &lt;90 mL/min

         10. History of drug, caffein(caffein &gt; 5 cups/day), smoking (cigarette &gt; 10/day) or
             alcohol abuse(alcohol &gt; 30 g/day)or Subjects who have ever drink within 7 days prior
             to drug administration

         11. Special diet known to interfere with the absorption, distribution, metabolism or
             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior
             to drug administration

         12. Donated blood within 60 days prior to dosing

         13. Participated in a previous clinical trial within 60 days prior to dosing

         14. Use of any other medication, including herbal products, within 10 days before dosing

         15. Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

